Thus, as anti-IL-6R interventions are continuing to be assessed for COVID-19, there is a potential opportunity for plant-based production of these expensive mAb treatments to ease the economic burden of treating hospitalized patients. The gene discussed is IL6R; the disease is COVID-19.